The latest national centralized procurement documents are released, and the pressure on distribution companies is also huge

Source: Medical Network

Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Supplementary Documents for the National Centralized Procurement of Medicines in Shanghai (GY-YD2021-1)", which detailed the contents of Shanghai area enterprise declaration, drug distribution, quality inspection, tripartite agreement, payment for goods, use of selected drugs, etc. Claim. Among them, there are several points worthy of attention.

1. Enterprise declaration

The drugs supplied in this centralized procurement should be in clinically commonly used packaging, and it is encouraged to provide drugs that meet the needs of more than 2 weeks of commonly used drugs for chronic diseases.

2. Drug delivery

A selected drug can only be entrusted to a drug distribution company to be responsible for distribution, and the designated distribution company should meet the following conditions:

(1) The scope of distribution of drugs by designated distribution companies in 2020 will cover all districts of the city;

(2) The designated distribution company has the ability and conditions to distribute the selected drugs to designated medical institutions of the city's medical insurance within 24 hours.

As a drug distribution company that undertakes distribution obligations, it is not allowed to purchase selected drugs through a third party. If the above-mentioned obligations cannot be fulfilled, once confirmed, the delivery qualification shall be cancelled and punishment shall be imposed according to regulations.

3. Quality inspection

In order to ensure that the quality of the selected drugs is stable and consistent before and after the selection, the selected companies must accept the work organization to use near-infrared spectroscopy modeling and other testing methods to test each batch of the selected drugs supplied. Declaring companies must accept random inspections of selected drugs at least twice a year and unannounced inspections if necessary.

4. Payment settlement

Within 5 working days after signing the "Tripartite Agreement on Purchase and Sale of Drugs Selected in Centralized Drug Purchasing", the working organization shall pay 50% of the total payment to the designated distribution company; the working organization shall pay 50% of the total purchase price to the designated delivery company; Pay 45% of the total payment to the designated delivery company; after completing the agreed purchase amount, the working agency will liquidate the designated delivery company's payment, and pay the remaining payment after the liquidation is completed.

From the above points, we can find that apart from being directly related to the selected companies and medical institutions, the national drug collection is also very closely related to the distribution companies, and it also places higher requirements on the distribution companies.

Distribution companies are also under great pressure

National centralized procurement is a hot spot that the pharmaceutical industry must experience every year, affecting the hearts of millions of medical professionals. And price reduction is a very important key word for national centralized procurement.

Judging from the price cuts of the 4+7, 4+7 expansion, the second and third batches of national centralized procurement, the keyword "price reduction" is so heavy for pharmaceutical companies and distribution companies.

According to the national procurement documents, the declared price must include taxes, distribution fees, etc. The actual supply price is the price of the actual supply of medical institutions. This price includes all taxes and distribution fees. of.

So, what is the delivery fee for the selected varieties in the centralized procurement? It is understood that the general distribution company will have 5-8 points of distribution fee for the distribution of medicines. According to the price of the country's centralized procurement, even if the distribution volume increases significantly compared with the past, the profit that the distributor earns from it is very small. With the continuous expansion of the scope of national procurement products, it will also have a huge impact on distribution companies. In the future, the polarization between small businesses and large businesses will become more and more obvious.

Prior to this, the person in charge of the Joint Procurement Office introduced to the media the four effects that national centralized procurement will achieve, including the transformation and upgrading of the pharmaceutical industry.

Promote the upgrading of the pharmaceutical enterprise structure and product structure by setting quality standards and purchasing in quantity; through the linkage of volume and price, guaranteeing use, and timely payment, standardizing the circulation order and purifying the industry ecology; promoting the scale of pharmaceutical distribution enterprises through regional linkage Intensification and modernization; allow fair competition between generic drugs that have passed consistency evaluation and original research drugs, and promote consistency evaluation.

And let’s look at the distribution rights of the previous batches of countries in the Shanghai area, which are basically divided between Shanghai Pharmaceuticals and State Control.

Some analysts said that from the perspective of national centralized procurement, not only did the drug manufacturers shuffle the brand, while reducing the price of drugs, it also placed higher requirements on drug distribution companies. In the future, with the expansion of the scope of national centralized procurement, large-scale distribution companies will also emerge from this competition, especially the mode of entrusting only one distribution company like Shanghai, which will greatly increase industry concentration. , The era of the strong and the strong has come.